Introduction
Sub-Saharan Africa is severely and disproportionally affected by the HIV and tuberculosis (TB) epidemics, with an estimated 19 million co-infected with HIV and Mycobacterium tuberculosis [1, 2] . HIV infection is a major risk factor for TB, and TB control programs across the continent have been overwhelmed by the increased case load attributable to HIV. TB in people with HIV is often disseminated and, in the absence of antiretroviral therapy (ART), a major cause of death [3, 4] . Widespread use of ART in sub-Saharan Africa has reduced the incidence of TB, although the rates of TB in many countries remain among the highest reported worldwide [2] .
Kidney disease in the setting of HIV is a common, complex, and a clinically significant problem [5] . The spectrum of kidney disease encompasses acute kidney injury (AKI), HIV-associated nephropathy (HIVAN), immune-complex kidney disease, diabetic and hypertensive nephropathy, opportunistic infections in addition to TB (e.g. cryptococcus, candida), malignancy (e.g. B-cell lymphoma) and drug toxicity from ART, co-trimoxazole and other antimicrobial chemotherapy [6] [7] [8] . In the setting of HIV/TB, kidney injury may result from any of these conditions as well as immune reconstitution inflammatory syndrome (IRIS) and acute or chronic effects of TB or antituberculous chemotherapy on the kidney. A kidney biopsy is often required to establish the diagnosis and guide therapeutic management, although this is rarely available outside selected major centres in sub-Saharan Africa.
The prevalence, incidence and histological characteristics of kidney disease in African HIV/TB patients remain largely unreported. A cross-sectional study from Cameroon evaluated renal function in 200 patients with HIV/ TB and variable duration of TB treatment and reported that 16 (8%) had impaired renal function [estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m 2 ) [9] . An autopsy study from Uganda reported renal TB in 8 (50%) of 16 patients with TB/HIV, HIVAN in 3 (19%) and other abnormalities in four patients; only one patient had normal kidneys [10] . We used observations from three distinct cohorts to describe the burden and spectrum of kidney disease in Africans with HIV/TB.
Methods
We used data from three cohorts: consecutive African patients with HIV/TB in London, United Kingdom; patients with HIV/TB who underwent kidney biopsy in Cape Town, South Africa and an autopsy series of people with HIV/TB in the pre-ART era in Abidjan, Cote d'Ivoire. Regulatory approvals were in place for each of the three cohorts; individual consent was not required.
In London, we identified all black African patients diagnosed with HIV/TB between 2004 and 2016 at King's College Hospital on a prospectively maintained database. To be included, patients were required to have HIV-1 infection diagnosed prior to, or up to 1 month after TB diagnosis, and a positive culture for M. tuberculosis or histology demonstrating granulomatous inflammation (with or without acid-fast bacilli). Demographic variables, HIV parameters, renal risk factors (hypertension and diabetes), details of TB treatment, and all available serum creatinine and proteinuria measurements and kidney biopsy reports were obtained. HIV parameters, TB outcomes and renal function were evaluated up to 12 months post-TB diagnosis.
In Cape Town, we identified consecutive patients with a clinical diagnosis of TB from a prospectively maintained kidney biopsy database at Groote Schuur Hospital between 2015 and 2017. To be included, patients were required to have had HIV infection at the time of kidney biopsy, and TB as evidenced by positive culture, nucleic acid amplification, urine lipoarabinomannan (LAM), elevated adenosine deaminase (ADA) levels in pleural or peritoneal fluid or granulomatous inflammation (with or without acid-fast bacilli) in any organ (including the kidney). Renal TB in this cohort was defined as the presence of granulomatous inflammation with or without acid-fast bacilli on kidney biopsy. Tenofovir toxicity was suspected in patients whose biopsies demonstrated acute tubular necrosis (ATN) with blebbing of the proximal mitochondrial cell membrane on light microscopy and predominant mitochondrial structural abnormalities on electron microscopy. Demographic variables, HIV parameters, hypertension, diabetes, TB treatment, ART and renal function at the time of biopsy, and at 3 and 6 months, were recorded. As renal, HIV and TB care took place in different locations, limited information on TB and HIV outcomes was available for this cohort.
In Abidjan, we identified patients with HIV/TB on a prospectively maintained database of autopsies in the pre-ART era performed by a single pathologist (S.B.L.) in 1991 in two hospitals [3] . To be included, patients were required to be HIV-1 and/or HIV-2 positive and to have pathological evidence of tuberculosis: acid-fast bacilli and/or (caseous or noncaseous) granulomatous inflammation in one or more organs. The diagnosis of TB in the kidney was histological: either nonreactive necrosis with numerous acid-fast bacilli ( Fig S1, http: //links.lww.com/ QAD/B466), or granulomatous inflammation with acidfast bacilli, or granulomatous inflammation without acidfast bacilli but TB in other organs and other infectious causes excluded.
Definitions
Acute kidney injury (AKI) was defined by increases in serum creatinine as per the Kidney Disease: Improving Global Outcomes (KDIGO) classification; stage 1 was defined by a 1.5-1.9 fold or at least 26.5 mmol/l increase from baseline; stage 2 by a 2.0-2.9-fold increase from baseline; stage 3 by a at least three-fold increase from baseline, a rise to at least 353.6 mmol/l, or the need for renal replacement therapy (RRT) [11] . To assess renal function at baseline and 12 months, creatinine values were converted to eGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, with application of the factor 1.159 for black ethnicity [12] ; CKD at 12 months was defined by an eGFR less than 60 ml/min per 1.73 m 2 for greater than 3 months, subdivided into stage 3 (eGFR 30-59 ml/min per 1.73 m 2 ), stage 4 (eGFR 15-29 ml/min per 1.73 m 2 ) and stage 5 (eGFR <15 ml/min per 1.73 m 2 ). End-stage kidney disease (ESKD) was defined by the need for permanent RRT. Proteinuria was assessed on randomly collected samples and expressed as urine protein/ creatinine ratio (uPCR, expressed in mg/mmol). The diagnosis of hypertension and diabetes was based on the use of medications to treat these conditions at the time of TB diagnosis or kidney biopsy.
Analyses
Demographic and clinical characteristics were described for each of the three cohorts, and kidney disease for the Abidjan and Cape Town cohorts. The incidence of AKI was calculated for participants in the London cohort, with follow-up included up to 12 months, the last clinic visit, or the date of the first AKI episode, whichever occurred earliest. In the Cape Town cohort, predictors of nonrecovery of kidney function (eGFR <60 ml/min per 1.73 m 2 or <30 ml/min per 1.73 m 2 at 6 months) were analysed using Cox regression.
Results
A total of 265 Africans with HIV/TB were included: 95 from London, 70 from Cape Town, and 100 from Abidjan (Table 1 and Table S1 , http://links.lww.com/ QAD/B466). The mean age across the three cohorts ranged from 36.4 to 39.1 years; most patients had advanced immunodeficiency and disseminated TB. Most patients in London were ART-naïve at TB diagnosis whereas in Cape Town most had initiated ART at the time of kidney biopsy; none of those in Abidjan had received ART. The TB diagnosis in Abidjan was made ante-mortem in 22% and at postmortem in 78%; TB was the main cause of death in 89% and the sole cause of death in 61%.
In London at TB diagnosis, the median eGFR was 118 [interquartile range (IQR) 88-129) ml/min/1.73 m 2 ; 13 patients (13.7%) had an eGFR <60 ml/min per 1.73 m 2 ( 
nephritis/drug toxicity (rifampicin/co-trimoxazole, n ¼ 2), drug-induced liver injury (n ¼ 2) and congestive cardiac failure (n ¼ 1). All 14 patients with stage 1 AKI had resolution of their kidney injury. Of the 12 patients who developed stage 2/3 AKI, three died, renal function normalized in four, partially recovered in three (allowing discontinuation of dialysis in two patients) and did not recover with the need for permanent RRT in the remaining two patients.
Chronic kidney disease
In the London cohort at 12 months post-TB diagnosis, the median eGFR was 107 (IQR 91-129) ml/min per 1.73 m 2 ( Table 2 ). Eleven patients (12.6%) had CKD stage 3/4/5; at TB diagnosis all but one had an eGFR less than 60 ml/min per 1.73 m 2 . Five patients (5.7%) presented with or progressed to ESKD. Seven patients had kidney biopsies; six showed HIVAN, one had interstitial nephritis, one had both HIVAN and interstitial nephritis and none had granulomata.
Mortality and kidney failure
Five patients died within 12 months of TB diagnosis (Table S1 , http://links.lww.com/QAD/B466). All five had kidney failure at the time of death: three had AKI with normal kidney function at TB diagnosis, and two had severe CKD (acute on chronic kidney failure, ESKD).
Kidney disease in the Abidjan and Cape Town cohorts
Pathological evidence of renal TB, ranging from single granulomas to vast numbers of acid-fast bacilli in glomeruli and tubule-interstitium ( Fig S1, http: // links.lww.com/QAD/B466), was present in 60%, interstitial nephritis in 31% (14 vs. 36% in those with antemortem and postmortem TB diagnoses, respectively), and HIVAN in 6% of autopsy cases in Abidjan; only 17% of patients in Abidjan had normal kidneys.
Many patients in Cape Town had multiple renal diseases. Renal TB was diagnosed in 61%, and HIVAN, ATN and pyelonephritis in 41, 69 and 17%, respectively (Table 3  and Table S2 , http://links.lww.com/QAD/B466). Tenofovir disoproxil fumarate (TDF) exposure was considered a contributing factor to the renal presentation in a single case. Immune complex kidney disease and amyloidosis were uncommon findings in either cohort.
Dialysis and reversibility of kidney failure in the Cape Town cohort Access to dialysis in government hospitals in South Africa is restricted and generally reserved for those with AKI and carefully selected patients with ESKD. In the 6 months following kidney biopsy, 44 (63%) patients required RRT; of these four were considered to have ESKD with no or minimal potential for reversibility. Dialysis was provided to the remaining 40 (91%) patients, of which 28 (70%) subsequently successfully discontinued RRT (17) DILS, diffuse infiltrative lymphocytosis syndrome; FSGS, focal and segmental glomerulosclerosis; GNR, Gram-negative rods; HIVAN, HIVassociated nephropathy.
a Granulomas were poorly formed in n ¼ 31; caseous in n ¼ 2 and contained AFBs in n ¼ 3. [postdialysis eGFR !60 (n ¼ 14), 30-59 (n ¼ 9), 15-29 (n ¼ 5) ml/min per 1.73 m 2 ). By 6 months, renal function had improved in the majority of patients (eGFR !60 ml/ min per 1.73 m 2 in 33%, eGFR 30-59 ml/min per 1.73 m 2 in 30%), and ESKD was present in 16 (23%) of the 70 participants (Table 2 and Table S2 , http:// links.lww.com/QAD/B466).
Age, gender, CD4
þ cell count, ART status and eGFR at biopsy were neither predictive of eGFR recovery nor were the presence of hepatitis B co-infection, hypertension or HIVAN. The presence of ATN on biopsy was associated with reduced risk of eGFR less than 60 ml/min per 1.73 m 2 at 6 months (hazard ratio 0.56, 95% CI 0.31-0.99; Table S3 , http://links.lww.com/QAD/B466).
Discussion
We used data from three complementary cohorts to study the incidence of AKI and CKD (London cohort), histological findings in patient with TB/HIV undergoing renal biopsies for clinical reasons and outcome of patients undergoing RRT for AKI (Cape Town cohort), and kidney disease of patients who died with HIV/TB in pre-ART era (Abidjan cohort). We report a high burden of kidney disease in African patients with HIV/TB. Data from London indicate that acute and chronic impairment of kidney function is common, and that 12% may require temporary or permanent RRT while receiving TB treatment. Data from London and Abidjan (constituting patients unselected for kidney disease) suggest that HIVAN may be present in about 6%, and that HIVAN is an important cause of ESKD in this population. Data from Cape Town (constituting patients with severe kidney disease) showed that HIVAN was common, acute and chronic kidney diseases frequently co-existed, and that kidney failure may recover in the majority of patients.
Most patients had severe immunodeficiency and disseminated TB with evidence of renal TB in 60% of cases. Immunodeficiency is a strong predictor of urine LAM positivity and mycobacteriuria, which are indicative of haematogenous dissemination of TB to the kidneys ( Fig  S1, http: //links.lww.com/QAD/B466) [13] . Immunodeficiency is also a major risk factor for AKI in the setting of HIV [14, 15] . The cause of AKI is often multifactorial, with infection, malignancy and liver disease compounded by reduced renal blood flow (hypotension or shock) and exposure to potentially nephrotoxic medications [14, 16] . Hence, the presence of TB in the kidneys should not be interpreted as TB being the sole cause of AKI or CKD. Kidney biopsies, wherever performed, frequently show ATN as well as evidence of underlying chronic kidney disease [17] . ART may contribute to (or cause) AKI through IRIS [18, 19] or direct ART nephrotoxicity, most commonly from TDF [20] . Although TDF was widely used in London and Cape Town, proximal tubulopathy was not observed in the London cohort and in the Cape Town cohort, TDF exposure was considered a contributing factor to the renal presentation in only one patient. A low rate of TDF toxicity is consistent with a previous study from our centre that did not find an association between TDF exposure and AKI [15] , and a large UK cohort study of almost 16 000 patients that reported black individuals to be at 80% reduced risk of treatmentlimiting TDF toxicity compared with those of (predominantly) white ethnicity [21] .
The prevalence of CKD 3-5 in the London cohort after 1 year was 13%, a finding that is consistent with findings from a study from Cameroon in which 13% of those on ART had an eGFR <60 ml/min/1.73 m 2 [9] . Data from the Cape Town cohort suggest that many of these individuals may have HIVAN, with or without sequelae of AKI and/or renal tuberculosis. The higher prevalence of HIVAN in the Cape Town vs. the London and Abidjan cohorts is likely explained by selection bias: participants in the Cape Town cohort all had severe kidney disease whereas the latter two cohorts constituted HIV/TB cases unselected for abnormalities of kidney function. As ART provides survival benefit in people with HIV/TB [22] as well as protection against kidney disease progression in individuals with HIVAN [7, 8, [23] [24] [25] , fully suppressive ART is a particular priority for patients with impaired renal function and/or proteinuria. However, despite unrestricted access to ART, 6% of patients in the London cohort developed ESKD. The incidence of ESKD among HIV/TB patients who receive treatment in Africa without monitoring of renal function could be substantially higher, especially in West Africa where apolipoprotein L1 (APOL1) risk alleles, which predispose to HIVAN, are highly prevalent and rates of viral suppression remain well below those reported in Southern and East Africa [1, 5, 26] .
Substantial reversibility of kidney failure was observed in the Cape Town cohort, even among those who required dialysis. These findings are consistent with a previous study of acute interstitial nephritis from Cape Town [27] . Specialist nephrology services are extremely sparse in subSaharan Africa and RRT is rarely available. Our results suggest that patients with HIV/TB may be appropriate candidates for acute dialysis in that 70% of those who received renal support regained native renal function and were able to subsequently discontinue dialysis. Although haemodialysis and haemofiltration are the standard modalities of RRT for patients with AKI in resourcerich settings, these are generally not available in resourcelimited healthcare settings [28] . However, acute peritoneal dialysis may be a lower cost alternative providing lifesaving renal support to patients with AKI [29] . Indeed, several acute peritoneal dialysis units have been successfully established across sub-Saharan Africa [30] , although considerable scale-up will be required to meet the needs of people with HIV/TB who develop AKI.
Uniquely this study benefits from three complimentary cohorts to provide insight into the prevalence, incidence and cause of kidney disease in Africans with HIV/TB. However, there are several limitations that should be acknowledged. Although participants in the three cohorts were identified on prospectively maintained databases, data collection was retrospective and invariably some data was missing where tests had not been performed or results could not be obtained. In London, not all patients with AKI or CKD underwent kidney biopsy, in Abidjan, patient's antemortem renal function and CD4 þ cell counts were not available, and among participants in Cape Town, viral load data were unavailable for more than half. Diagnosis of renal TB in the Cape Town cohort was based on identifying granulomatous inflammation (with or without acid fast bacilli) in the kidney; this may have resulted in an underestimation of the prevalence of renal TB as those with advanced immunodeficiency may be unable to mount a granulomatous inflammatory response, or an overestimation of the prevalence of renal TB as in some cases, this pathological abnormality may have been because of another infection, drug toxicity or vasculitis. Additionally, this prevalence estimate may be underestimated as (nongranulomatous) interstitial nephritis was not considered diagnostic of renal TB. Although interstitial nephritis may be indicative of rifampicin or co-trimoxazole-induced renal toxicity [27] , interstitial nephritis in the Abidjan cohort was more common in those with a postmortem TB diagnosis (many also had HIV-diagnosed postmortem), suggesting this may also reflect a localized or systemic inflammatory immune response to TB in the kidney, in the setting of uncontrolled HIV replication. Finally, there may be a degree of overlap in clinical and pathological features of ATN from TDF toxicity and other causes, such as sepsis; we may, therefore, have underestimated the contribution of TDF to the burden of kidney disease in the Cape Town cohort.
Conclusion
Acute and chronic kidney disease was common in Africans with HIV/TB in all three study cohorts, and approximately 10% of patients in London required dialysis. These data suggest that in much of sub-Saharan Africa where RRT is unavailable, kidney failure may be an important cause of death in patients with HIV/TB.
